BR112018002681A2 - ?composto, composição, e, método para tratamento de infecção por hiv? - Google Patents

?composto, composição, e, método para tratamento de infecção por hiv?

Info

Publication number
BR112018002681A2
BR112018002681A2 BR112018002681A BR112018002681A BR112018002681A2 BR 112018002681 A2 BR112018002681 A2 BR 112018002681A2 BR 112018002681 A BR112018002681 A BR 112018002681A BR 112018002681 A BR112018002681 A BR 112018002681A BR 112018002681 A2 BR112018002681 A2 BR 112018002681A2
Authority
BR
Brazil
Prior art keywords
compound
composition
hiv infection
treating hiv
compounds
Prior art date
Application number
BR112018002681A
Other languages
English (en)
Inventor
Narasimhulu Naidu B
F Kadow John
Peese Kevin
Patel Manoj
Wang Zhongyu
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of BR112018002681A2 publication Critical patent/BR112018002681A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

são descritos compostos de fórmula (i), incluindo sais farmaceuticamente aceitáveis, composições farmacêuticas compreendendo os compostos, métodos para produzir os compostos e seu uso na inibição de integrasse hiv e tratamento daqueles infectados por hiv ou aids.
BR112018002681A 2015-08-10 2016-08-10 ?composto, composição, e, método para tratamento de infecção por hiv? BR112018002681A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562202973P 2015-08-10 2015-08-10
PCT/IB2016/054827 WO2017025913A1 (en) 2015-08-10 2016-08-10 Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
BR112018002681A2 true BR112018002681A2 (pt) 2019-04-24

Family

ID=56851648

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018002681A BR112018002681A2 (pt) 2015-08-10 2016-08-10 ?composto, composição, e, método para tratamento de infecção por hiv?

Country Status (12)

Country Link
US (1) US10138253B2 (pt)
EP (1) EP3334741A1 (pt)
JP (1) JP2018522924A (pt)
KR (1) KR20180035908A (pt)
CN (1) CN108026113A (pt)
AU (1) AU2016305338A1 (pt)
BR (1) BR112018002681A2 (pt)
CA (1) CA2994517A1 (pt)
IL (1) IL257155A (pt)
RU (1) RU2018106494A (pt)
WO (1) WO2017025913A1 (pt)
ZA (1) ZA201800657B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109232562A (zh) * 2018-10-24 2019-01-18 康化（上海）新药研发有限公司 一种7-氮杂吲哚-5-氯-6-羧酸的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL369567A1 (en) 2001-09-26 2005-05-02 Bayer Pharmaceuticals Corporation 1,6-naphthyridine derivatives as antidiabetics
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CA2705312C (en) 2007-11-15 2013-06-25 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
ES2463720T3 (es) 2007-11-16 2014-05-29 Gilead Sciences, Inc. Inhibidores de la replicación del virus de inmunodeficiencia humana
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
MX2012007410A (es) 2009-12-23 2012-07-17 Univ Leuven Kath Compuestos antivirales novedosos.
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8906929B2 (en) * 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP2016512507A (ja) 2013-03-13 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
CN105189511B (zh) 2013-03-13 2017-05-24 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
EP2970274B1 (en) * 2013-03-14 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US9409922B2 (en) * 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
JP2018522924A (ja) 2018-08-16
WO2017025913A1 (en) 2017-02-16
AU2016305338A1 (en) 2018-03-01
CN108026113A (zh) 2018-05-11
US10138253B2 (en) 2018-11-27
IL257155A (en) 2018-03-29
ZA201800657B (en) 2019-07-31
US20180230165A1 (en) 2018-08-16
CA2994517A1 (en) 2017-02-16
EP3334741A1 (en) 2018-06-20
RU2018106494A (ru) 2019-09-12
KR20180035908A (ko) 2018-04-06

Similar Documents

Publication Publication Date Title
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
EA201890425A1 (ru) Противовирусные фосфодиамидные сложноэфирные бета-аминокислотные соединения
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112018005904A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
BR112018005870A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
CL2016002179A1 (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b.
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
NZ733174A (en) Quinazoline derivatives used to treat hiv
BR112017011941A2 (pt) compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona substituídos 3 para o tratamento e profilaxia de infecção viral
BR112018077015A2 (pt) derivados de ácido borônico e usos terapêuticos dos mesmos
BR112015021027A8 (pt) compostos terapêuticos, seus usos, e composições farmacêuticas
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201590674A1 (ru) Производные 5-фенокси-3h-пиримидин-4-она и их применение в качестве ингибиторов обратной транскрипазы вич
BR112018013251A2 (pt) compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
BR112017028456A2 (pt) composto, e, método de prevenção e/ou tratamento de hiv
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
BR112016016854A2 (pt) Derivados de 7-oxo-1,6-diazabiciclo[3.2.1]octana, seu processo de preparação e seu uso, composição farmacêutica e seu uso pedidos de patente relacionados

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]